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Objective: To describe gene expression in murine chondrocytes stimulated with IL-6 family cytokines
and the impact of deleting Suppressor of Cytokine Signaling-3 (SOCS-3) in this cell type.
Method: Primary chondrocytes were isolated from wild type and SOCS-3edeﬁcient (Socs3D/Dcol2) mice
and stimulated with oncostatin M (OSM), IL-6 plus the soluble IL-6 receptor (IL-6/sIL-6R), IL-11 or leu-
kemia inhibitory factor (LIF) for 4 h. Total RNA was extracted and gene expression was evaluated by
microarray analysis. Validation of the microarray results was performed using Taqman probes on RNA
derived from chondrocytes stimulated for 1, 2, 4 or 8 h. Gene ontology was characterized using DAVID
(database for annotation, visualization and integrated discovery).
Results: Multiple genes, including Bcl3, Junb, Tgm1, Angptl4 and Lrg1, were upregulated in chondrocytes
stimulated with each gp130 cytokine. The gene transcription proﬁle in response to OSM stimulation was
pro-inﬂammatory and was highly correlated to IL-6/sIL-6R, rather than IL-11 or LIF. In the absence of
SOCS-3, OSM and IL-6/sIL-6R stimulation induced an interferon (IFN)-like gene signature, including
expression of IL-31ra and S100a9.
Conclusion: While each gp130 cytokine induced a transcriptional response in chondrocytes, OSM- and IL-
6/sIL-6R were the most potent members of this cytokine family. SOCS-3 plays an important regulatory
role in this cell type, as it does in hematopoietic cells. Our results provide new insights into a hierarchy of
gp130-induced transcriptional responses in chondrocytes that is normally restrained by SOCS-3 and
suggest therapeutic inhibition of OSM may have beneﬁt over and above antagonism of IL-6 during in-
ﬂammatory arthritis.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Cartilage loss is a characteristic feature of inﬂammatory and
degenerative arthritis. Chondrocytes are multi-functional cells that
are responsible for producing, maintaining and remodeling the
cartilaginous extracellular matrix (ECM) during skeletal develop-
ment and throughout life. How chondrocytes switch to a catabolic.P. Wicks, Reid Rheumatology
liza Hall Institute of Medical
ustralia.
ternational. Published by Elsevier Lprogram in inﬂammatory and degenerative arthritis remains rela-
tively poorly understood.
The contribution of IL-6 to the pathogenesis of inﬂammatory
arthritis has been highlighted by recent therapeutic successes with
Tocilizumab, an anti-IL-6 receptor antibody, and Tofacitinib, a Jak
kinase (JAK)1/3 inhibitor1,2. IL-6 is a member of a family of cyto-
kines (referred to as gp130 cytokines) that bind to speciﬁc a-chain
receptors, which then engage a common b-subunit, known as
gp130, to initiate intracellular signaling. Formation of the ligan-
d:receptor:gp130 complex leads to recruitment of JAK1, JAK2 and
Tyk2 kinases that phosphorylate cytoplasmic tyrosine residues on
gp130, which creates docking sites for the binding of latent Signal
Transducers and Activators of Transcription (STAT)-1, STAT3 andtd. All rights reserved.
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translocate to the nucleus, binding to promoter/enhancer regions of
STAT-responsive genes to activate or repress transcription.
The Suppressor of Cytokine Signaling (SOCS) proteins are induced
by activation of multiple receptors and forms an endogenous nega-
tive feedback loop to restrain signal transduction. Of the eight SOCS
family members, Suppressor of Cytokine Signaling-3 (SOCS-3) is the
key regulator of cellular responses downstream of the gp130 re-
ceptor3. It acts by blocking access to key cytoplasmic residues on
gp130, inhibiting autoactivation of JAKs and recruiting an ubiquitin
ligase complex that targets JAKs for proteasome mediated degra-
dation3,4. Global deletion of SOCS-3 is embryonically lethal due to
excess leukemia inhibitory factor (LIF) signaling5. Using a conditional
gene targeting strategy to delete SOCS-3 in chondrocytes, we
recently demonstrated its pivotal role in regulating the duration of
cytokine signal transduction in this non-hematopoietic cell type6.
These ﬁndings prompted us to examine the effect of SOCS-3 on the
global transcriptional responses of chondrocytes following exposure
to IL-6 and other members of the IL-6 family.
In this study, we compared the differential gene expression of
primary articular chondrocytes in response to oncostatin M (OSM),
IL-6/sIL-6R, IL-11 or LIF stimulation, and found surprisingly diver-
gent responses. We also found evidence for a hierarchy within this
cytokine family, with OSM and IL-6/sIL-6R being the most potent
stimulators of gene expression in chondrocytes, causing profound
and selective effects that were highly correlated. In SOCS-
3edeﬁcient chondrocytes stimulated with OSM and IL-6/sIL-6R,
there was a switch to an IFN-like gene signature, demonstrating
that SOCS-3 also regulates the qualitative nature of the response to
gp130 cytokines in chondrocytes.
Method
Animals
Socs3D/Dcol2 conditional knockout mice were generated as pre-
viously described6. Socs3ﬂ/ﬂ littermates served as controls in all
experiments, unless otherwise stated. WT C57BL/6J mice were
obtained from the Walter and Eliza Hall Institute (WEHI) animal
services (Kew, Victoria, Australia). Mice were aged 5e6 days for
ex vivo chondrocyte culture. The WEHI Animal Ethics Committee,
Parkville, Australia, approved all animal procedures.
Isolation of primary epiphyseal chondrocytes for stimulation with
cytokines
Chondrocytes were harvested as described previously7. Prox-
imal tibial and distal femoral epiphyses from 15 mice (5e6 days-
old) mice were harvested and pooled epiphyses were incubated
with 0.25% trypsin for 1 h at 37C, prior to digestion with 2 mg/ml
type II collagenase in Dulbecco's modiﬁed Eagle's medium
(DMEM)e5% fetal calf serum (FCS) (Worthington, Lakewood, NJ),
followed by shaking overnight at 37C. Cells were washed with
DMEMe10% FCS and counted.
For stimulation assays, chondrocytes were plated at 1.5e2 105
cells/well in 96-well ﬂat-bottom plates containing DMEMe10% FCS,
with three technical replicates. Cells were stimulated with 100 ng/
ml recombinant human IL-6/soluble IL-6R (sIL-6R) (both fromR&D
Systems) at equimolar concentrations, or with murine OSM (R & D
Systems), IL-11 or LIF (WEHI) at 100 ng/ml.
RNA preparation and hybridization for microarray analysis
Primary chondrocytes (conﬁrmed by expression of type II
collagen) were harvested as described above and stimulated withgp130 cytokines for 4 h. Total RNA from three independent ex-
periments was prepared from cultured cells using the RNeasy mini
kit (Qiagen). RNA quality was veriﬁed using the Agilent Bioanalyzer
2100, using the NanoChip protocol. A total of 500 ng RNA was
labeled using the Ambion Total Prep RNA ampliﬁcation kit (Cat. No.
e IL1791). The quantity of labeled product was ascertained using
the Agilent Bioanalyzer 2100, with the NanoChip protocol. A total of
1.5 mg of labeled complimentary RNA (cRNA) was then prepared for
hybridization to the Illumina Mouse-6v2 Expression Beadchip by
preparing a probe cocktail (cRNA at 0.05 mg/ul) that includes GEX-
HYB Hybridization Buffer (supplied with the beadchip). Hybrid-
izations were done at the Australian Genome Research Facility Ltd
(AGRF) using standard Illumina protocols.
A total hybridization volume of 30 ml was prepared for each
sample and 30 ml loaded into a single array on the Illumina Mouse-
6v2 Expression Beadchip, hybridized at 58C for 16 h in an ovenwith
a rocking platform. After hybridization, the chip was washed ac-
cording to the manufacturer's protocols. After washing, chips were
coupled with Cy3 and scanned in the Illumina iScan Reader. The
scanner operating software, GenomeStudio, was used to convert
array signals into a TXT ﬁle for analysis.Bioinformatics
The limma package8 was used for bioinformatic analysis. The
probe summary proﬁles and the control probe summary proﬁles
were read into R (http://www.r-project.org). Probe annotationswere
taken from the latest bead manifest ﬁle (MouseWG-
6_V2_0_R3_11278593_A.txt). Gene symbols provided by Illumina
were converted to current gene symbols using the
alias2SymbolTable function and the Bioconductor annotation
package org.Mm.e.g.db9. Intensities were corrected for background
andnormalizedusing the neqc (normexpbackground correction and
quantile normalization using control probes) algorithm10. This
algorithm uses negative controls to estimate the background in-
tensity level on each array. Probes were ﬁltered as non-expressed if
these failed to achieve a detection P-value of 0.05 on at least three
arrays, leaving 22984 probes for analysis. Normalized log2 expres-
sion valueswere analyzed using linearmodels, adjusting for possible
batch effects between replicate experiments. Empirical array
weights were used to allow for quality differences between RNA
samples11. Differential expression was assessed using empirical
Bayes moderated t-statistics12. The false discovery rate was
controlled using the Benjamini and Hochberg method13. Gene
ontology (GO) analyses were performed using DAVID (database for
annotation, visualization and integrated discovery) v6.714. Venn di-
agramsweredrawnusing theVennDiagrampackage (http://www.r-
project.org). Gene lists were cross-referenced with the Interferon
Regulated Gene (IRG) database15. Gene lists and functional annota-
tions were derived from the same microarray dataset.Quantitative polymerase chain reaction (qPCR)
Total RNAwas prepared from cultured cells (derived from pooled
epiphyseal cartilage from ten mice) using the RNeasy mini kit (Qia-
gen). Complementary DNA was prepared by reverse transcription.
Quantitative-PCR was performed on a Bio-Rad C100 Thermal Cycler
instrument and expression of Gapdh (Mm99999915_g1), Il19
(Mm01288324_m1), Saa1 (Mm00656927_g1), Bcl3 (Mm00504
306_m1), Ccl7 (Mm00443113_m1), Sphk1 (Mm00448841_g1) and
Lrg1 (Mm01278767_m1) transcript levels were determined using
Taqman probes. Transcript expression was determined using the
2DDCt method16, with values normalized against those for Gapdh.
Fold changes were measured relative to unstimulated controls.
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Student's unpaired 2-tailed t test was used to analyze gene
expression by qPCR. P < 0.05 was considered signiﬁcant.
Results
Identiﬁcation of gene expression in WT mouse chondrocytes in
response to stimulation with gp130 cytokines
Primary epiphyseal chondrocytes from (Socs3ﬂ/ﬂ) WT mice were
treated with OSM, IL-6/sIL-6R, IL-11 or LIF for 4 h. Transcriptional
proﬁling of stimulated and unstimulated cells showed that OSM
was the most potent stimulus, inducing 1844 differentially
expressed genes in chondrocytes (false discovery rate (FDR) < 0.05,
Fig. 1(A)). In contrast, 788 genes were differentially expressed after
IL-6/sIL-6R treatment, 633 by LIF and 14 genes by IL-11 stimulation.
OSM also induced the most distinct changes in gene expression,
activating 1104 unique genes compared to 276 by LIF and 86 by IL-
6/sIL-6R. Of the genes affected by IL-11, nonewere unique. A total ofFig. 1. Microarray analysis of wild-type (WT) chondrocytes stimulated with gp130 cytok
discovery rate < 0.05) in primary epiphyseal chondrocytes stimulated with OSM, IL-6 in con
table summarizes the total number and the number of unique differentially expressed genes
four gp130 cytokines. (C) Scatter plots of log2-fold expression changes induced by OSM com
without any ﬁltering for statistical signiﬁcance. Three independent experiments were cond13 genes were differentially expressed in response to all gp130
cytokines [Fig. 1(B)]. These include activators of MMP-1 transcrip-
tion e Bcl317 and Junb18, angiogenic factors e Angptl419 and Lrg120
and a mediator of cartilage matrix mineralization e Tgm121. Scat-
terplots of log2-fold changes were used to examine whether
changes in gene expression induced by OSM and IL-6 family cyto-
kines in chondrocytes were correlated or distinct. Changes induced
by OSM correlated most highly with IL-6/sIL-6R, compared to IL-11
or LIF. However, OSM induced more unique changes in gene
expression than IL-6/sIL-6R [Fig. 1(C)].
Comparison of induced genes in WT chondrocytes stimulated with
OSM or IL-6/sIL-6R
Given the profound effects of OSM and IL-6/sL-6R on WT
chondrocytes, we examined the similarities and differences in
more detail. The twenty most highly up-regulated and down-
regulated genes (FDR < 0.05) in chondrocytes in response to OSM
or IL-6/sIL-6R stimulation are shown in Table I. Validation of
selected differentially expressed genes in chondrocytes stimulatedines. (A) Venn diagram showing the number of differentially expressed genes (false
junction with soluble IL-6R (IL-6/sIL-6R), IL-11, and leukemia inhibitory factor (LIF). The
for each cytokine. (B) Log2-fold changes and P-values for the 13 genes responding to all
pared to the changes induced by other gp130 cytokines. All expressed genes are shown
ucted. Each biological replicate utilized epiphyseal chondrocytes from 15 mice.
Table I
Wild-type (WT) chondrocytes were stimulated with OSM or IL-6/sIL-6R and the top 20 up- and down-regulated genes induced by OSM (A and B), or up- and down-regulated
genes induced by IL-6/sIL-6R (C and D) are shown. Each table shows the 20 largest fold changes amongst genes with FDR <0.05.
Probe ID Symbol Gene description log FC P value FDR
A. OSM
Up-regulated
11134 Il19 Interleukin-19 6.35 1.9E-13 2.5E-10
20567 Tgm1 Transglutaminase 1 5.29 3.5E-20 8.0E-16
18413 Saa1 Serum amyloid A1 4.58 1.4E-12 1.1E-09
17222 Ptges Prostaglandin E synthase 4.37 3.3E-13 3.8E-10
5816 Ccl7 Chemokine (CeC motif) ligand 7 4.24 8.0E-12 4.2E-09
6969 Cxcl2 Chemokine (C-X-C motif) ligand 2 4.23 2.8E-11 1.2E-08
19679 Socs3 Suppressor of Cytokine Signaling 3 4.18 3.7E-11 1.4E-08
4681 Barx2 BARX homeobox 2 3.98 1.5E-12 1.1E-09
13463 Lrg1 Leucine-rich alpha-2-glycoprotein 1 3.85 7.0E-13 6.4E-10
13929 Mcoln2 Mucolipin 2 3.80 5.5E-10 1.3E-07
17902 Rgs16 Regulator of G-protein signaling 16 3.68 1.7E-14 6.2E-11
19799 Sphk1 Sphingosine kinase 1 3.65 3.7E-13 3.9E-10
16468 Plau Plasminogen activator, urokinase 3.58 4.4E-06 1.8E-04
11171 Il6 Interleukin-6 3.49 8.7E-09 1.1E-06
11110 Il13ra1 Interleukin-13 receptor, alpha 1 3.45 1.2E-08 1.4E-06
4972 Bcl3 B-cell lymphoma 3 3.37 3.2E-15 3.6E-11
9762 Gjb2 Gap junction protein, beta 2 3.36 1.2E-13 2.2E-10
6960 Cxcl1 Chemokine (C-X-C motif) ligand 1 3.32 5.0E-13 4.8E-10
9661 Gcnt2 Glucosaminyl (N-acteyl) transferase 2 3.32 1.8E-14 6.2E-11
10418 Has1 Hyaluronan synthase 1 3.30 2.7E-13 3.4E-10
B. OSM
Down-regulated
160066 Smpd3 Sphingomyelin phosphodiesterase 3 5.22 5.3E-14 1.1E-10
20327 G0s2 G0/G1 switch 2 3.39 2.8E-10 7.3E-08
6650524 Cacna1d Ca2þ channel, Voltage-dependent, L type, alpha 1D subunit 3.28 1.4E-11 6.9E-09
3830296 Gal3st1 Galactose-3-O-Sulfotransferase 1 3.22 8.3E-11 2.7E-08
7200035 Fgfr3 Fibroblast growth factor receptor 3 3.03 4.2E-09 6.0E-07
2570427 Mef2c Myocyte enhancer factor 2c 2.87 7.1E-12 4.0E-09
5260619 Sp7 Sp7 transcription factor 2.83 1.5E-09 2.7E-07
6590630 Lpar4 Lysophosphatidic acid receptor 4 2.66 1.1E-09 2.2E-07
2340671 Mtap7d3 MAP7 domain containing 3 2.56 6.1E-10 1.3E-07
5870097 Id4 Inhibitor of DNA binding 4, dominant negative helix-loop-helix 2.55 8.8E-09 1.1E-06
50148 Myl9 Myosin, light chain 9, regulatory 2.53 2.6E-07 1.8E-05
2260082 Chrna4 Cholinergic receptor, nicotinic, alpha 4 2.48 1.0E-10 3.0E-08
6290743 Fgf21 Fibroblast growth factor 21 2.42 1.8E-10 4.9E-08
6760474 Zcchc5 Zinc ﬁnger, CCHC domain containing 5 2.34 4.4E-07 2.8E-05
2510382 Limch1 LIM and calponin homology domains 1 2.33 9.2E-13 8.2E-10
1410168 Tmem100 Transmembrane protein 100 2.32 3.6E-12 2.3E-09
10577 Mrgprf MAS-related GPR, member F 2.30 2.3E-11 1.1E-08
4010632 Snai2 Snail family zinc ﬁnger 2 2.27 2.9E-13 3.5E-10
3310736 Zfp385c Zinc ﬁnger protein 385c 2.27 2.5E-11 1.1E-08
160402 Ogn Osteoglycin 2.25 5.7E-08 5.2E-06
C. IL-6/sIL-6R
Up-regulated
430131 Ccl7 Chemokine (CeC motif) ligand 7 4.71 7.5E-13 2.5E-09
5260487 Saa1 Serum amyloid A1 4.69 9.1E-13 2.6E-09
4150750 Cxcl2 Chemokine (C-X-C motif) ligand 2 4.34 1.8E-11 3.1E-08
3940168 Il19 Interleukin-19 4.27 1.5E-09 1.1E-06
2370639 Ptges Prostaglandin E synthase 4.25 6.9E-13 2.5E-09
6270040 Tgm1 Transglutaminase 1 3.93 8.9E-17 2.1E-12
110112 Ccl2 Chemokine (CeC motif) ligand 2 3.71 5.4E-08 1.7E-05
3610082 Cxcl1 Chemokine (C-X-C motif) ligand 1 3.64 6.0E-14 3.4E-10
840044 Hp Haptoglobin 3.47 2.3E-10 2.6E-07
4070020 Bcl3 B-cell lymphoma 3 3.25 8.4E-15 9.7E-11
5670731 Il6 Interleukin-6 3.19 5.4E-08 1.7E-05
1230142 Gdnf Glial cell derived neurotrophic factor 3.14 1.5E-09 1.1E-06
1570594 Socs3 Suppressor of Cytokine Signaling 3 3.09 2.2E-08 8.2E-06
3890528 Rgs16 Regulator of G-protein signaling 16 3.04 1.8E-12 3.7E-09
3400086 Gpr84 G protein-coupled receptor 84 2.96 2.6E-08 9.0E-06
6650458 Nfkbiz NF-kappa-B inhibitor, zeta 2.94 2.3E-10 2.6E-07
290097 Lrg1 Leucine-rich alpha-2-glycoprotein 1 2.93 3.7E-10 3.8E-07
6060349 Zc3h12a Zinc ﬁnger CCCH-type containing 12A 2.88 1.6E-08 5.9E-06
2970598 Map3k8 Mitogen-activated protein kinase kinase kinase 8 2.85 2.6E-07 5.3E-05
3370397 Barx2 BARX homeobox 2 2.85 2.5E-09 1.4E-06
D. IL-6/sIL-6R
Down-regulated
160066 Smpd3 Sphingomyelin phosphodiesterase 3 2.37 9.3E-07 1.4E-04
50148 Myl9 Myosin, light chain 9, regulatory 2.31 1.3E-06 1.8E-04
5870097 Id4 Inhibitor of DNA binding 4, dominant negative helix-loop-helix 2.20 1.5E-07 3.4E-05
3830296 Gal3st1 Galactose-3-O-Sulfotransferase 1 2.18 2.2E-07 4.5E-05
20327 G0s2 G0/G1 switch 2 2.09 2.7E-06 3.0E-04
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Table I (continued )
Probe ID Symbol Gene description log FC P value FDR
3130136 Acta2 Actin, alpha 2, smooth muscle, aorta 1.92 2.2E-06 2.7E-04
6290452 Kcnk2 Kþ channel, subfamily K, member 2 1.84 1.4E-07 3.3E-05
7100142 Kctd4 Kþ channel tetramerization domain containing 4 1.83 2.3E-05 1.6E-03
6330181 Frzb Frizzled-related protein 1.81 4.7E-05 2.9E-03
2030450 Acta1 Actin, alpha 1, skeletal muscle 1.72 7.4E-06 6.7E-04
4780180 C1qtnf3 C1q and TNF-related protein 3 1.66 8.1E-05 4.4E-03
2570427 Mef2c Myocyte enhancer factor 2c 1.64 6.4E-07 1.0E-04
6650524 Cacna1d Ca2þ channel, Voltage-dependent, L type, alpha 1D subunit 1.63 8.5E-06 7.4E-04
2340671 Mtap7d3 MAP7 domain containing 3 1.60 3.6E-06 3.8E-04
7200035 Fgfr3 Fibroblast growth factor receptor 3 1.58 1.6E-04 7.8E-03
1990243 Lrrc17 Leucine rich repeat containing 17 1.56 6.5E-06 6.1E-04
6590630 Lpar4 Lysophosphatidic acid receptor 4 1.54 1.9E-05 1.4E-03
5490379 Ppp1r1b Protein phosphate 1, regulatory (inhibitor) subunit 1B 1.53 1.1E-05 8.8E-04
2810546 Nphp1 Nephronophthisis 1 (Juvenile) 1.53 7.2E-05 4.1E-03
3780082 Lpar1 Lysophosphatidic acid receptor 1 1.46 1.0E-05 8.4E-04
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is a critical regulator of the gp130 cytokine-mediated JAK/STAT
signaling cascade in chondrocytes6. It was highly up-regulated in
WT chondrocytes in response to OSM (Table IA) and IL-6/sIL-6R
(Table 1C) stimulation. Multiple genes associated with joint
inﬂammation, including Ccl2, Cxcl2, Il6, Ptges and Saa1 were also
highly up-regulated in WT chondrocytes stimulated under these
conditions, comprising a pro-inﬂammatory gene signature. Genes
that might contribute to chronic inﬂammatory responses, but
which, to our knowledge, have not been previously associated with
chondrocytes, including Ccl7, Il19, Lrg1 and Tgm1, were up-
regulated in chondrocytes stimulated with OSM or IL-6/sIL-6R.
Genes down-regulated in WT chondrocytes in response to OSM
(Table IB) and IL-6/sIL-6R (Table 1D) stimulation, included sphin-
gomyelin phosphodiesterase 3 (Smpd3), G0/G1 switch 2 (G0s2),Fig. 2. Validation of induced gene expression in wild-type (WT) chondrocytes stimulated
analyze (A) Il19 (B) Ccl7 (C) Saa1 (D) Lrg1 (E) Bcl3 and (F) Sphk1mRNA expression in mouse ep
4 and 8 h. Results show sets of experimental data from three independent biological experi
** ¼ P < 0.01 and *** ¼ P < 0.001.calcium channel (Cacna1d), ﬁbroblast growth factor receptor 3
(Fgfr3) and myocyte enhancer factor 2c (Mef2c). Full lists of the
differentially expressed genes in WT chondrocytes induced by each
gp130 cytokine are shown in Supplementary Tables 1e4.
Expression of pro-inﬂammatory mediators Il19, Ccl7 (MCP-3)
and Saa1 has been shown in RA synovial tissue22e24. IL-19 induces
IL-6 production and reduces synoviocyte apoptosis22. CCL7 (MCP-3)
mediates monocyte recruitment and macrophage activation25.
SAA1 is a potent inﬂammatory stimulus that mediates the chemo-
attraction of monocytes, neutrophils and T cells and induces tran-
scription of matrix metalloproteinases in RA26,27. Leucine-rich
alpha-2-glycoprotein 1 (Lrg1) is a regulator of angiogenesis that
mediates its effects by binding to endoglin, which, in the presence
of TGF-b1, signals via the Smad 1/5/8 pathway20. Increased
expression of Lrg1 in chondrocytes stimulated with OSM and IL-6/with OSM or IL-6/sIL-6R. Quantitative-polymerase chain reaction was performed to
iphyseal chondrocytes left unstimulated or stimulated with OSM or IL-6/sIL-6R for 1, 2,
ments. Each experiment utilized epiphyseal chondrocytes from ten mice. * ¼ P < 0.05,
Table II
Top annotation clusters identiﬁed by DAVID functional analyses of genes responding to (A and B) OSM or (C and D) IL-6/sIL-6R in wild-type (WT) chondrocytes. Separate
functional analyses were conducted for up- and down-regulated genes.
Category Term P value
A. OSM
Up-regulated
Annotation Cluster 1 Enrichment Score: 7.1
GOTERM_BP_FAT GO:0009611 Response to wounding 3.7E-09
GOTERM_BP_FAT GO:0006954 Inﬂammatory response 4.6E-09
GOTERM_BP_FAT GO:0006952 Defense response 7.9E-08
Annotation Cluster 2 Enrichment Score: 7.3
GOTERM_BP_FAT GO:0012501 Programmed cell death 2.2E-08
GOTERM_BP_FAT GO:0006915 Apoptosis 3.6E-08
GOTERM_BP_FAT GO:0016265 Death 7.0E-08
GOTERM_BP_FAT GO:0008219 Cell death 9.2E-08
Annotation Cluster 3 Enrichment Score: 4.7
GOTERM_MF_FAT GO:0004672 Protein kinase activity 1.0E-07
GOTERM_MF_FAT GO:0004674 Protein serine/threonine kinase activity 1.3E-07
GOTERM_BP_FAT GO:0006468 Protein amino acid phosphorylation 3.9E-07
GOTERM_BP_FAT GO:0006793 Phosphorus metabolic process 1.2E-06
GOTERM_BP_FAT GO:0006796 Phosphate metabolic process 1.2E-06
GOTERM_MF_FAT GO:0017076 Purine nucleotide binding 3.7E-06
GOTERM_BP_FAT GO:0016310 Phosphorylation 4.0E-06
GOTERM_MF_FAT GO:0032555 Purine ribonucleotide binding 1.4E-05
GOTERM_MF_FAT GO:0032553 Ribonucleotide binding 1.4E-05
GOTERM_MF_FAT GO:0000166 Nucleotide binding 4.3E-05
B. OSM
Down-regulated
Annotation Cluster 1 Enrichment Score: 5.4
GOTERM_BP_FAT GO:0001501 Skeletal system development 1.1E-09
GOTERM_BP_FAT GO:0060348 Bone development 7.6E-07
GOTERM_BP_FAT GO:0001503 Ossiﬁcation 1.3E-05
GOTERM_BP_FAT GO:0051216 Cartilage development 1.2E-04
GOTERM_BP_FAT GO:0001649 Osteoblast differentiation 8.4E-04
Annotation Cluster 2 Enrichment Score: 2.3
GOTERM_BP_FAT GO:0002062 Chondrocyte differentiation 1.5E-03
GOTERM_BP_FAT GO:0060349 Bone morphogenesis 4.3E-03
GOTERM_BP_FAT GO:0060350 Endochondral bone morphogenesis 5.0E-02
GOTERM_BP_FAT GO:0001958 Endochondral ossiﬁcation 1.4E-01
Annotation Cluster 3 Enrichment Score: 2.1
GOTERM_MF_FAT GO:0016791 Phosphatase activity 2.8E-03
GOTERM_MF_FAT GO:0008138 Protein tyrosine/serine/threonine phosphatase activity 5.3E-03
GOTERM_MF_FAT GO:0004721 Phosphoprotein phosphatase activity 6.0E-03
GOTERM_BP_FAT GO:0016311 Dephosphorylation 9.9E-03
GOTERM_MF_FAT GO:0004725 Protein tyrosine phosphatase activity 1.2E-02
GOTERM_BP_FAT GO:0006470 Protein amino acid dephosphorylation 1.2E-02
C. IL-6/sIL-6R
Up-regulated
Annotation Cluster 1 Enrichment Score: 10.7
GOTERM_BP_FAT GO:0006954 Inﬂammatory response 2.7E-13
GOTERM_BP_FAT GO:0006952 Defense response 1.3E-12
GOTERM_BP_FAT GO:0009611 Response to wounding 2.3E-12
GOTERM_BP_FAT GO:0002526 Acute inﬂammatory response 1.5E-07
Annotation Cluster 2 Enrichment Score: 6.2
GOTERM_BP_FAT GO:0006915 Apoptosis 1.9E-09
GOTERM_BP_FAT GO:0012501 Programmed cell death 2.8E-09
GOTERM_BP_FAT GO:0008219 Cell death 1.8E-08
GOTERM_BP_FAT GO:0016265 Death 2.9E-08
GOTERM_BP_FAT GO:0043067 Regulation of programmed cell death 9.2E-08
GOTERM_BP_FAT GO:0010941 Regulation of cell death 1.1E-07
GOTERM_BP_FAT GO:0042981 Regulation of apoptosis 1.9E-07
GOTERM_BP_FAT GO:0043069 Negative regulation of programmed cell death 3.1E-05
GOTERM_BP_FAT GO:0060548 Negative regulation of cell death 3.3E-05
GOTERM_BP_FAT GO:0043066 Negative regulation of apoptosis 7.7E-05
GOTERM_BP_FAT GO:0006916 Anti-apoptosis 9.2E-03
Annotation Cluster 3 Enrichment Score: 5.9
GOTERM_BP_FAT GO:0043067 Regulation of programmed cell death 9.2E-08
GOTERM_BP_FAT GO:0010941 Regulation of cell death 1.1E-07
GOTERM_BP_FAT GO:0042981 Regulation of apoptosis 1.9E-07
GOTERM_BP_FAT GO:0043065 Positive regulation of apoptosis 2.7E-06
GOTERM_BP_FAT GO:0043068 Positive regulation of programmed cell death 3.0E-06
GOTERM_BP_FAT GO:0010942 Positive regulation of cell death 3.5E-06
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Table II (continued )
Category Term P value
GOTERM_BP_FAT GO:0006917 Induction of apoptosis 8.3E-06
GOTERM_BP_FAT GO:0012502 Induction of programmed cell death 8.3E-06
D. IL-6/sIL-6R
Down-regulated
Annotation Cluster 1 Enrichment Score: 5.7
GOTERM_BP_FAT GO:0060348 Bone development 2.4E-08
GOTERM_BP_FAT GO:0001501 Skeletal system development 2.0E-07
GOTERM_BP_FAT GO:0001503 Ossiﬁcation 4.3E-06
GOTERM_BP_FAT GO:0001649 Osteoblast differentiation 5.8E-06
GOTERM_BP_FAT GO:0051216 Cartilage development 1.6E-04
Annotation Cluster 2 Enrichment Score: 2.7
GOTERM_BP_FAT GO:0001894 Tissue homeostasis 5.2E-05
GOTERM_BP_FAT GO:0060249 Anatomical structure homeostasis 1.6E-04
GOTERM_BP_FAT GO:0048871 Multicellular organismal homeostasis 4.3E-04
GOTERM_BP_FAT GO:0048873 Homeostasis of number of cells within a tissue 2.4E-03
GOTERM_BP_FAT GO:0048872 Homeostasis of number of cells 8.6E-02
GOTERM_BP_FAT GO:0042592 Homeostatic process 9.2E-02
Annotation Cluster 3 Enrichment Score: 2.0
GOTERM_BP_FAT GO:0006357 Regulation of transcription from RNA polymerase II promoter 3.8E-04
GOTERM_BP_FAT GO:0045892 Negative regulation of transcription, DNA-dependent 2.3E-03
GOTERM_BP_FAT GO:0000122 Negative regulation of transcription from RNA polymerase II promoter 2.5E-03
GOTERM_BP_FAT GO:0051253 Negative regulation of RNA metabolic process 2.5E-03
GOTERM_BP_FAT GO:0006350 Transcription 3.8E-03
GOTERM_MF_FAT GO:0030528 Transcription regulator activity 3.9E-03
GOTERM_BP_FAT GO:0051252 Regulation of RNA metabolic process 5.0E-03
GOTERM_MF_FAT GO:0003700 Transcription factor activity 5.8E-03
GOTERM_BP_FAT GO:0006355 Regulation of transcription, DNA-dependent 7.0E-03
GOTERM_MF_FAT GO:0003677 DNA binding 7.5E-03
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genesis during inﬂammatory arthritis. Bcl3 expression is a co-factor
for MMP-1 transcription and was previously found to be up-
regulated by IL-1b stimulation in a chondrocyte cell line17.
Sphingosine-1-phosphate (S1P) is a sphingolipidmetabolite and
was elevated in the synovial tissue and synovial ﬂuid of patients
with RA28,29. S1P promotes joint inﬂammation by enhancing
cytokine production and proliferation of synovial ﬁbroblasts30.
Sphingosine kinase (Sphk1) phosphorylates sphingosine to sphin-
gosine-1-phosphate (S1P). Inhibition of SphK1 via small interfering
RNA (siRNA) reduced the incidence and severity of CIA31. Taken
together, these results reveal a potent pro-inﬂammatory gene
signature can be produced by chondrocytes in response to both
OSM and IL-6/sIL-6R stimulation.Comparison of inﬂammatory gene signatures in WT chondrocytes in
response to OSM or IL-6/sIL-6R stimulation
To explore biological processes that are altered in WT chon-
drocytes in response to OSM or IL-6/sIL-6R stimulation, differen-
tially expressed genes were analyzed by DAVID functional
annotation clustering (Table II AeD). Genes that were up-regulated
in WT chondrocytes in response to OSM (Table IIA) or IL-6/sIL-6R
(Table 2C) stimulation were highly enriched for GO terms “In-
ﬂammatory response”, “Defense response”, “Response to wound-
ing” and “Acute inﬂammatory response”. Gene expression changes
associated with these biological processes overlapped with more
speciﬁc functions, such as “Cytokine activity” and “Chemokine ac-
tivity” (data not shown). OSM and IL-6/sIL-6R stimulation also had
a positive impact on gene signatures associated with cell death.
Function annotation clustering of genes that were down-
regulated in WT chondrocytes stimulated with OSM or IL-6/sIL-
6R highlighted pathways associated with “Bone and Cartilage
development”, “Ossiﬁcation”, “Tissue homeostasis” and other
cellular processes (including phosphatase activity, cell cycle, andchromatin organization) (Table IIB and IID and data not shown).
This observation is in keepingwith a cytokine-induced switch away
from normal chondrocyte functions.
To compare responses to OSM or IL-6/sIL-6R, we focused on
genes associated with the GO biological processes “Cytokine ac-
tivity”, “Metallopeptidase activity” and “Enzyme inhibitor activity”
(Fig. 3). Here, we found that inﬂammatory cytokines, including Il24,
Il19, and Il33, were mainly induced after OSM simulation, whereas
genes involved in chemotactic activity, including Ccl20, Cxcl10 and
Ccl2, were more highly expressed following IL-6/sIL-6R stimulation
(FDR < 0.05, Fig. 3(A)). Amongst genes associated with “Metal-
lopeptidase activity”, Adamts1, Adamts4, Adam9 were more highly
expressed after OSM stimulation, whereas Adamts7, Pappa,
Adamts13 and Cpm were higher after IL-6/SIL-6R treatment (FDR
<0.05, [Fig. 3(B)]. Chondrocytes also secrete inhibitors of catabolic
enzymes. Members of the tissue inhibitor of metalloproteinase
(TIMP) family are endogenous inhibitors of MMPs and ADAMTSs.
Assessment of the biological process “Enzyme inhibitor activity”
showed equivalent changes between OSM and IL-6/sIL-6R stimu-
lation in the induction of Timp1, Timp2 and Timp3 expression
[Fig. 3(C)]. Together, these results conﬁrm that while transcrip-
tional responses of chondrocytes to OSM and IL-6/sIL-6R are highly
correlated, different transcriptional responses are activated by each
cytokine.SOCS-3 regulates the nature of the inﬂammatory gene signature in
murine chondrocytes stimulated with OSM and IL-6/sIL-6R
Our previous study of inﬂammatory arthritis in mice with con-
ditional deletion of SOCS-3 in chondrocytes demonstrated marked
exacerbation of all features of disease6. We therefore undertook
transcriptional proﬁling in response to individual members of the
gp130 cytokine family in SOCS-3 deﬁcient chondrocytes [Fig. 4(A)].
Transcriptional proﬁling of stimulated and unstimulated SOCS3-
deﬁcient chondrocytes identiﬁed 3695 differentially expressed
Fig. 3. Differences between OSM and IL-6/sIL-6R stimulation for genes associated with
gene ontology (GO) terms for joint inﬂammation, cartilage degradation and enzyme
inhibitor activity. For each of the GO terms (A) “Cytokine activity” (B) “Metal-
lopeptidase activity” and (C) Inhibitors of Enzyme Activity”, genes are shown that were
differentially expressed (FDR < 0.05) after OSM relative to IL-6/sIL-6R stimulation in
wild-type chondrocytes. Black bars show genes that were more highly up-regulated
after OSM stimulation and white bars show genes that were more up-regulated af-
ter IL-6/sIL-6R stimulation. The horizontal axis shows the log2 expression difference
between cells stimulated by that cytokine relative to those stimulated by the other.
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induced 1748 differentially expressed genes, 698 by LIF and 116
by IL-11 stimulation. OSM induced the most distinct changes in
gene expression, activating 2311 unique genes compared to 37 by
LIF and 440 by IL-6/sIL-6R. All differentially expressed genes
induced by IL-11 stimulation were shared with other gp130 cyto-
kines. These ﬁndings conﬁrm that SOCS-3 regulates a large number
of genes, comprising a distinctive transcriptional response of
chondrocytes to each gp130 cytokine.
Genetic deletion of SOCS-3 expression in hematopoietic cells
and chondrocytes exacerbates inﬂammatory arthritis6,32. To char-
acterize the effects of SOCS-3 on global gene transcription in more
detail, the expressed genes from OSM- or IL-6/sIL-6R-stimulatedSocs3D/Dcol2 chondrocytes (corrected for unstimulated Socs3D/Dcol2
chondrocytes) were compared with OSM- or IL-6/IL-6R-stimulated
littermate controls (corrected for unstimulated littermate chon-
drocytes). This analysis identiﬁed 169 SOCS-3edependent genes
that are induced by OSM stimulation, including Il24, S100a9 and the
peptidase Adamts4 [Fig. 4(B)]. At the same timepoint, only 15 SOCS-
3edependent genes were induced after IL-6/sIL-6R stimulation
[Fig. 4(C)], including S100a8, Il33, and Il31ra. Il24 is a member of the
IL-10 family of cytokines. Elevated levels of IL-24 were found in
synovial ﬂuid and plasma of RA patients and were associated with
CCL2 production and neutrophil recruitment33. S100A8 and S100A9
are damage-associated molecular patterns (DAMPs) that can be
detected in the synovial tissue of OA34 and human chondrocytes
stimulated with S100A8 and S100A9 up-regulated catabolic
markers, including MMPs, cytokines and chemokines35. IL-33 is a
member of the IL-1 family and blockade of IL-33 signaling reduces
the severity of CIA36. IL-31 binds to a heterodimeric receptor con-
sisting of IL-31RA and OSMRb to initiate signal transduction. IL-31
induces a broad range of cellular responses in hematopoietic
cells, including cell proliferation and the induction of cytokines and
chemokines37. To our knowledge, whether IL-31 has such func-
tional effects on chondrocytes has not been examined. Interest-
ingly, we found SOCS-2 is also expressed by chondrocytes,
explaining the gigantism found in SOCS-2 knockout mice38.
Many of the genes induced by OSM and IL-6/sIL-6R in SOCS-
3edeﬁcient chondrocytes were associated with type I and II
interferon (IFN) regulated ‘gene signatures’ (OSM e 51 out of 145
genes, 35%; 16 type I IFN, 11 type II IFN and 25 shared; IL-6/sIL-
6Re4 out of 15 genes, 33%; 1 type II IFN and 3 shared). As normally
only approximately 13% of all genes are ‘IFN responders’, this
enrichment is highly signiﬁcant. We observed similar effects when
SOCS-3 was deleted in hepatocytes39, suggesting the enhanced
transcription of IFN related genes might be due to the increased
duration of STAT1 activation in Socs3D/Dcol2 chondrocytes stimu-
lated with OSM or IL-6/sIL-6R.
Discussion
In this study, we characterized global gene expression changes
in chondrocytes after stimulation with each gp130 cytokine and in
the presence or absence of endogenous SOCS-3. Within the gp130
family, OSM and IL-6/sIL-6R induced the most profound effects on
transcriptional proﬁles in WT chondrocytes. Differentially
expressed genes in Socs3D/Dcol2 chondrocytes after OSM and IL-6/
sIL-6R stimulation revealed an IFN-like signature. These ﬁndings
identify gene networks in chondrocytes that are crucially depen-
dent on SOCS-3 activity and are potentially related to multiple as-
pects of inﬂammatory arthritis.
IL-6edeﬁcient mice are protected against synovitis and cartilage
degradation in a number of models of experimental arthritis1. In
clinical trials, the humanized anti-IL-6R antibody, Tocilizumab,
inhibited progression of structural joint damage and induced sus-
tained improvements in cartilage and bone biomarkers in RA40e42.
Our previous study showed that chondrocytes express low levels of
membrane-bound IL-6R and appear to rely on IL-6 trans-signaling
tomount a cellular response6. Here, we found that during the early-
phase response (i.e., within 4 h), IL-6/sIL-6R stimulation activated
pro-inﬂammatory biological pathways in chondrocytes, and
induced the up-regulation of cytokines (Il19, Saa1, and Il6) and
chemokines (Ccl2, Ccl7, Cxcl1, Cxcl2). Collectively, our results sug-
gest that anti-IL-6R reduces chondrocyte-mediated joint damage
by blockade of IL-6 trans-signaling.
Differential expression analysis demonstrated that gene
expression changes in OSM-stimulated chondrocytes closely
resembled that of IL-6/sIL-6R. Previous studies have suggested a
Fig. 4. Microarray analysis of SOCS-3edeﬁcient chondrocytes stimulated with gp130 cytokines. (A) Venn diagram showing the number of differentially expressed genes
(FDR < 0.05) in Socs3D/Dcol2 chondrocytes stimulated with OSM, IL-6/sIL-6R, IL-11 and LIF. The table summarizes the total number and the number of unique differentially expressed
genes for each cytokine. Genes showing SOCS-3-dependency in their expression changes after (B) OSM or (C) IL-6/sIL-6R-stimulation. Genes are shown that produced signiﬁcantly
different (FDR < 0.05) cytokine-induced expression changes in Socs3D/Dcol2 chondrocytes compared to wild-type chondrocytes. Log FC values are delta log2-fold changes between
the two genotypes. For OSM, the 10 largest positive and negative delta log2-fold changes are shown. For IL-6/sIL-6R, all 15 signiﬁcant genes are shown. Gene lists were cross-
referenced with the Interferon Regulated Gene (IRG) database.
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antibody prior to disease onset ameliorated the severity of CIA43.
Genome-wide analyses have reported the up-regulation of MMPs
in chondrocyte cell lines exposed to OSM44. Our ﬁndings expand
upon these results. We demonstrate profound changes in gene
expression proﬁles in primary chondrocytes in response to OSM
stimulation, including those coding for cytokines, chemokines,
angiogenic factors and other pro-inﬂammatory mediators.
Furthermore, changes in gene expression in chondrocytes stimu-
lated with OSM also associate with biological processes of cell
death, suggesting that activation of apoptotic pathways might be
also represent a response of chondrocytes to OSM. Pro-
inﬂammatory cytokines, such as IL-1b and IL-6/sIL-6R, play an
important role in cartilage destruction by inhibiting type II
collagen mRNA expression in articular chondrocytes45,46. Our re-
sults suggest that chondrocytes can down-regulate or suspendcellular processes responsible for ECM production and mainte-
nance, as early as four hours after stimulation with IL-6/sIL-6R or
OSM.
Functional annotation clustering demonstrated the enrichment
of inﬂammatory responses in chondrocytes stimulated with OSM
or IL-6/sIL-6R. By comparing the magnitude of changes in gene
expression for speciﬁc biological processes, we found OSM induced
greater changes in gene expression for inﬂammatory cytokines,
while IL-6/sIL-6R inﬂuenced genes associated with chemokine ac-
tivity. Our results also highlight differences in peptidase gene
expression in chondrocytes stimulated with OSM or IL-6/sIL-6R, at
least during the timeframe examined. However, these differences
were not uni-directional, as both OSM and IL-6/sIL-6R induced
equivalent changes in gene expression for the GO term “Enzyme
inhibitor activity”, which included members of the chondro-
protective TIMP family. Murine primary chondrocytes express
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transmembrane IL-6R6. Differential gene expression analysis
revealed IL-11 and LIF induced a smaller number of genes
compared to OSM and IL-6/sIL-6R.We showed previously that IL-11
and LIF induce milder catabolic effects on cartilage degradation,
aggrecan expression and inﬂammatory arthritis, both in vitro and
in vivo6. Together, these results imply that while endogenous IL-11
and LIF can induce joint inﬂammation in vivo, pro-inﬂammatory
effects on chondrocytes are much less potent compared to OSM
and IL-6/sIL-6R.
Genetic deletion of SOCS-3 prolonged STAT3 and STAT1 phos-
phorylation in hematopoietic cells, augmenting responses to IL-6
and exacerbating inﬂammatory arthritis32,39. Intra-articular in-
jections of OSM or IL-6/sIL-6R into the knee joints of Socs3D/Dcol2
mice exacerbated synovitis and cartilage destruction6. Our analyses
identiﬁed 169 SOCS-3edependent genes induced by OSM and 15
that were induced by IL-6/sIL-6R trans-signaling. The absence of
SOCS-3 had amajor effect on chondrocyte responses to OSM and IL-
6/sIL-6R in particular, with greater transcription of genes associated
with joint inﬂammation and cartilage degradation, including Il24,
S100a8, S100a9, Il33, Trim21, and Adamts4. These ﬁndings support
the notion of a broadly active, pro-inﬂammatory role for chon-
drocytes in inﬂammatory arthritis, which is normally restrained by
SOCS-3. S100 molecules bind to receptor for advanced glycation
end products (RAGE) and might act as DAMPS that promote local
joint inﬂammation. Chondrocytes may therefore be an important
source of DAMPs during arthritis and, together with enhanced
cytokine and chemokine production by chondrocytes lacking SOCS-
3, could potentially explain the dramatic ampliﬁcation of inﬂam-
matory arthritis we observed in Socs3D/Dcol2 mice6.
Intriguingly, many differentially expressed genes induced in
SOCS-3edeﬁcient chondrocytes after OSM and IL-6/sIL-6R stimu-
lation are not normally associated with gp130 cytokine responses,
but rather, more closely correlated with an IFN signature. Previous
studies have reported that, in the absence of STAT3, IL-6-
stimulation elicited an IFN-g-like response in liver cells that was
accompanied by prolonged STAT1 activation39. Gene expression
analysis of SOCS-3edeﬁcient liver cells stimulated with IL-6
revealed the up-regulation of IFN-g-induced genes that were not
observed in IL-6 stimulated cells containing functional SOCS-3 al-
leles. In this study, deletion of SOCS-3 resulted in the selective in-
duction of type I and II IFN-related genes in chondrocytes. These
data indicate that SOCS-3 not only regulates the magnitude and
duration of JAK/STAT signaling, but can also inﬂuence the nature of
the transcriptional response. Exacerbated inﬂammatory arthritis
due to SOCS-3 deﬁciency may therefore be caused by prolonged
STAT1/IFN-mediated, as well as STAT3-mediated responses after
stimulation with gp130 cytokines.
Our analysis has demonstrated the transcriptional response of
chondrocytes to gp130 cytokines. By utilizing samples from three
independent experiments, the study controls for between-
individual biological variation, however, it remains a snapshot
of the overall inﬂammatory response of this cell-type. The time
point chosen may not indicate gene expression changes (both
direct and indirect) during later stages (i.e., > 4 h) of chondrocyte
responses to gp130 cytokine stimulation. Transcriptional re-
sponses are clearly inﬂuenced by cytokine receptor levels and
receptor signaling. We have shown these vary on chondrocytes
within the gp130 family and that the response to IL-6 depends on
trans-signaling. The kinetics of STAT1, STAT3 and STAT5 activation
in chondrocytes also differs between OSM and IL-6/sIL-6R, with
more prolonged phosphorylation of STAT1, STAT3 and STAT5
observed in response to OSM stimulation6. Furthermore, the
murine OSM receptor can initiate STAT5B activation directly via
receptor-bound JAK2, without interacting with the gp130subunit47. The diversity in transcription proﬁles that we found
most likely reﬂects these differences in OSM- and IL-6/sIL-6R-
induced signal transduction.
Our study has important strengths in that it uses primary
chondrocytes and comprehensively evaluates early (and hence
more likely to be direct) responses to individual members of the
gp130 cytokine family. This unbiased examination of the differen-
tial effects of gp130 cytokines in primary mouse chondrocytes
demonstrates a hierarchy of responsiveness and a crucial regula-
tory role for SOCS-3. We provide new insights into the similarities
and differences in gene expression in chondrocytes in response to
OSM or IL-6/sIL-6R stimulation during the early-phase of the in-
ﬂammatory response. In particular, we have identiﬁed gene sig-
natures in chondrocytes associated with a range of pro-
inﬂammatory responses and catabolic programs. Furthermore,
the effects of OSM and IL-6/sIL-6R on gene expression are markedly
altered in the absence of SOCS-3, demonstrating its crucial physi-
ological role in this non-hematopoietic cell type. How the physio-
logical role of SOCS-3 in chondrocytes might be compromised by
age, or sustained exposure to an inﬂammatory environment, is the
subject of ongoing investigation. The data presented here highlight
the potent effects of OSM on catabolic and inﬂammatory responses
in chondrocytes and adds to evidence that therapeutic targeting of
OSM could be beneﬁcial for inﬂammatory joint disease.
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